Insider Selling: STERIS (NYSE:STE) Director Sells 1,481 Shares of Stock

STERIS plc (NYSE:STE) Director Richard Breeden sold 1,481 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total transaction of $310,284.31. Following the transaction, the director owned 38,964 shares of the company’s stock, valued at approximately $8,163,347.64. This trade represents a 3.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

STERIS Price Performance

Shares of NYSE:STE traded up $1.90 during trading hours on Thursday, hitting $212.09. 983,510 shares of the company’s stock traded hands, compared to its average volume of 796,322. STERIS plc has a 52 week low of $195.14 and a 52 week high of $269.44. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.54 and a current ratio of 2.09. The company’s fifty day simple moving average is $217.68 and its two-hundred day simple moving average is $239.61. The company has a market cap of $20.70 billion, a price-to-earnings ratio of 26.74 and a beta of 0.93.

STERIS (NYSE:STE) last posted its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a net margin of 13.18% and a return on equity of 14.15%. The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter last year, the business posted $2.74 EPS. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, equities analysts anticipate that STERIS plc will post 11.18 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 8th will be given a dividend of $0.63 per share. The ex-dividend date is Monday, June 8th. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. STERIS’s dividend payout ratio (DPR) is 31.78%.

Institutional Trading of STERIS

A number of hedge funds have recently bought and sold shares of the company. NewEdge Advisors LLC lifted its stake in STERIS by 2.1% during the first quarter. NewEdge Advisors LLC now owns 8,062 shares of the medical equipment provider’s stock valued at $1,783,000 after buying an additional 168 shares in the last quarter. Glenmede Trust Co. NA lifted its stake in STERIS by 12.2% during the first quarter. Glenmede Trust Co. NA now owns 4,120 shares of the medical equipment provider’s stock valued at $911,000 after buying an additional 447 shares in the last quarter. Segall Bryant & Hamill LLC lifted its stake in STERIS by 5.2% during the first quarter. Segall Bryant & Hamill LLC now owns 19,159 shares of the medical equipment provider’s stock valued at $4,237,000 after buying an additional 940 shares in the last quarter. Groupe la Francaise lifted its stake in STERIS by 9.4% during the first quarter. Groupe la Francaise now owns 18,514 shares of the medical equipment provider’s stock valued at $4,094,000 after buying an additional 1,589 shares in the last quarter. Finally, Western Wealth Management LLC purchased a new stake in STERIS during the first quarter valued at about $25,000. 94.69% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on STE shares. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 16th. KeyCorp reduced their price objective on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Weiss Ratings lowered shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $270.00 price objective on shares of STERIS in a research note on Thursday, May 21st. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $278.00.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.